OK-432 therapy for lymphangioma in children: Why and how does it work?

被引:157
作者
Ogita, S [1 ]
Tsuto, T [1 ]
Nakamura, K [1 ]
Deguchi, E [1 ]
Tokiwa, K [1 ]
Iwai, N [1 ]
机构
[1] TSUTO CLIN,KYOTO,JAPAN
关键词
OK-432; therapy; lymphangioma; cystic hygroma; intralesional therapy; sclerosing therapy;
D O I
10.1016/S0022-3468(96)90478-9
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Intralesional injection of OK-432 (lyophilized incubation mixture of group A Streptococcus pyogenes of human origin) is safe and effective therapy for lymphangioma. The authors evaluated the mechanism of this therapy in 6 patients who had cystic lymphangioma. The intracystic fluid of the cystic lymphangioma was aspirated before and after (on days 1 and 4) the OK-432 therapy. Changes in cell populations and cytokine productions in each aspirated fluid were analyzed. White blood cells in the intracystic fluid increased markedly in number. Before OK-432 therapy, 96% of the intracystic white blood cells were lymphocytes, and the remaining were neutrophils and macrophages, On day 1, the percentages of neutrophils and macrophages increased to 72% and 21%, respectively. On day 4, the percentage of lymphocytes increased to 72%. Flow cytometry analysis using monoclonal antibodies showed that the number of natural killer cells (CD56(+)) and T cells (CD3(+)) had increased. The activity of cytotoxic tumor necrosis factor (TNF) and interleukin-6 increased immediately after OK-432 injection and remained high in titer until day 4, These findings suggest that the white blood cells induced and activated by OK-432, and the cytokines (including TNF) produced by these cells increased the endothelial permeability, and thus the accelerated lymph drainage and increased lymph flow led to shrinkage of the cystic spaces. (C) 1996 by W.B. Saunders Company
引用
收藏
页码:477 / 480
页数:4
相关论文
共 22 条
  • [1] EFFECTS OF TUMOR-NECROSIS-FACTOR ON TUMOR-CELL PLASMA-MEMBRANE PERMEABILITY
    ANGHILERI, LJ
    ROBERT, J
    [J]. TUMORI, 1987, 73 (03) : 269 - 271
  • [2] ISHIDA N, 1985, STREPTOCOCCAL PREPAR, P60
  • [3] ISHIDA N, 1990, BIOTHERAPY, V4, P155
  • [4] KATANO M, 1982, CANCER, V50, P62, DOI 10.1002/1097-0142(19820701)50:1<62::AID-CNCR2820500113>3.0.CO
  • [5] 2-0
  • [6] MECHANISM OF INDUCTION OF ENDOGENOUS TUMOR NECROSIS FACTOR IN ASCITES OF OVARIAN-CANCER PATIENTS BY OK-432, A STREPTOCOCCAL PREPARATION
    MORI, H
    ITOH, N
    TAMAYA, T
    [J]. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 1989, 11 (01) : 33 - 53
  • [7] MORIYA Y, 1993, CANCER IMMUNOL IMMUN, V35, P245
  • [8] NODA K, 1987, CANCER, V60, P2394
  • [9] OK-432 THERAPY FOR UNRESECTABLE LYMPHANGIOMAS IN CHILDREN
    OGITA, S
    TSUTO, T
    DEGUCHI, E
    TOKIWA, K
    NAGASHIMA, M
    IWAI, N
    [J]. JOURNAL OF PEDIATRIC SURGERY, 1991, 26 (03) : 263 - 270
  • [10] OGITA S, 1987, BRIT J SURG, V74, P690